Abstract
Background: Sentinel lymph node (SLN) mapping for melanoma and breast cancer has greatly enhanced the identification of micrometastases in many patients, thereby upstaging a subset of these patients. The purpose of this study was to see if SLN mapping technique could be used to identify SLNs in colorectal cancer and to assess its impact on pathological staging and treatment.
Methods: At the time of surgery, 1 ml of Lymphazurin 1% was injected subserosally around the tumor without injecting into the lumen. The first to fourth blue nodes identified were considered the SLNs, which have the highest probability to contain metastases. A standard oncological resection of the bowel was then performed. Multilevel microsections of the SLNs, including a detailed pathological examination of the entire specimen, was performed.
Results: SLN was successfully identified in 85 (98.8%) of 86 patients. In 85 patients, there were 1367 (16 per patient) lymph nodes examined, of which 140 (1.6 per patient) were identified as SLNs. In 53 (95%) of 56, of whom the SLNs were without metastases (negative), all other non-SLNs also were negative. In 29 (34% of 85) patients, SLNs were positive for metastases; in 14 of the 29 patients, other non-SLNs also were positive in addition to the SLNs. In the other 15 of the 29 patients (18% of 85 patients), SLNs were the only site of metastases, and all other non-SLNs were negative. In 7 patients (8.2% of 85 patients), micrometastases were identified only in 1 or 2 of the 10 sections of a single SLN. In five of seven patients, such micrometastases were detected by hematoxylin and eosin staining and immunohistochemistry; in the other two patients, it was detected only by immunohistochemistry. In patients with negative SLNs, the rate of occurrence of micrometastases in non-SLNs was 5 (0.4%) of 1184 lymph nodes.
Conclusions: SLN mapping can be performed easily in colorectal cancer patients, with an accuracy of more than 95%. The identification of submicroscopic lymph node metastases by this technique may have upstaged these patients (18%) from stage I/II to stage III disease, who may then benefit from further adjuvant chemotherapy.
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, Wingo P. Cancer statistics 1998. CA Cancer J Clin 1998;48:12–14.
Cohen AM, Kelsen D, Saltz L, et al. Adjuvant therapy for colorectal cancer. Curr Prob Cancer 1998;22:5–65.
Gusterson B. Are micrometastases clinically relevant? Br J Hosp Med 1992;47:247–248.
Broll R, Schauer V, Schimmelpenning H, Strik M, Woltmann AL, Best R. Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas. Dis Colon Rectum 1997;40:1465–1471.
Greenson J, Isenhard C, Rice R, Mojzisk C, Houchens D, Martin E. Identification of occult micro metastases in pericolic lymph nodes of Dukes’ B colorectal Cancer patients using monoclonal antibodies against cytokeratin and CC49. Cancer 1994;73:563–569.
Herrera-Omelas L, Justiniano J, Castillo N, et al. Metastasis in small lymph nodes from colon cancer. Arch Surg 1987;122:1253–1256.
Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.
Krag DN, Weaver DI, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335–339.
Giuliano A, Jones R, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345–2350.
Albertini J, Lyman G, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818–1822.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saha, S., Wiese, D., Badin, J. et al. Technical Details of Sentinel Lymph Node Mapping in Colorectal Cancer and Its Impact on Staging. Ann Surg Oncol 7, 120–124 (2000). https://doi.org/10.1007/s10434-000-0120-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0120-z